| Capital Increase in Genmab as a Result of Employee Warrant Exercise |
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. |
globenewswire.com |
2025-02-25 16:30:00 |
Czytaj oryginał (ang.) |
| Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference |
Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano and C hief D evelopment O fficer Judith Klimovsky will participate in a fireside chat at the 4 5 th Annual TD Cowen Health Care Conference in Boston , Massachusetts at 1 : 50 PM EST ( 7: 5 0 PM CET ) on March 3 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations. |
globenewswire.com |
2025-02-19 11:14:00 |
Czytaj oryginał (ang.) |
| Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon |
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects. |
seekingalpha.com |
2025-02-18 04:25:53 |
Czytaj oryginał (ang.) |
| Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript |
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call February 12, 2025 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Tahamtan Ahmadi - Chief Medical Officer Judith Klimovsky - Chief Development Officer Conference Call Participants Jonathan Chang - Leerink Partners Paul Jeng - Guggenheim Securities, LLC Asthika Goonewardene - Truist Securities Yifeng Liu - HSBC Xian Deng - UBS Yaron Werber - TD Securities Matthew Phipps - William Blair Qize Ding - Redburn Atlantic Justin Smith - Bernstein Vikram Purohit - Morgan Stanley Rajan Sharma - Goldman Sachs Operator Hello, and welcome to the Genmab Full Year 2024 Financial Results Conference Call. As a reminder, this conference call is being recorded. |
seekingalpha.com |
2025-02-14 11:32:11 |
Czytaj oryginał (ang.) |
| Notice to Convene the Annual General Meeting of Genmab A/S |
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy is attached. |
globenewswire.com |
2025-02-13 08:00:00 |
Czytaj oryginał (ang.) |
| Genmab Files Annual Report with the U.S. Securities and Exchange Commission |
Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2024. Both reports are available via the SEC's website, www.sec.gov and Genmab's website, www.genmab.com. |
globenewswire.com |
2025-02-12 15:14:00 |
Czytaj oryginał (ang.) |
| Genmab Publishes 2024 Annual Report |
Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. |
globenewswire.com |
2025-02-12 13:01:00 |
Czytaj oryginał (ang.) |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab |
Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. |
globenewswire.com |
2025-01-23 17:08:00 |
Czytaj oryginał (ang.) |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 |
Company Announcement Net sales of DARZALEX ® in 2024 totaled USD 11,670 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest of the world. |
globenewswire.com |
2025-01-22 08:23:00 |
Czytaj oryginał (ang.) |
| GMAB vs. QGEN: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-01-16 14:41:12 |
Czytaj oryginał (ang.) |
| Genmab (GMAB) Upgraded to Buy: Here's What You Should Know |
Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-14 15:00:32 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Genmab (GMAB) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-14 12:46:23 |
Czytaj oryginał (ang.) |
| Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 4 3 rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 1 4 , 202 5 , 12 :00 AM CET on January 15, 2025 . The live and archived webcast of the presentation will be available on Genmab's website at https://ir.genmab.com/events-presentations. |
globenewswire.com |
2025-01-03 15:56:00 |
Czytaj oryginał (ang.) |
| Genmab to Hold 2024 R&D Update and ASH Data Review Meeting |
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. |
globenewswire.com |
2024-12-11 10:20:00 |
Czytaj oryginał (ang.) |
| Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) |
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), d. |
businesswire.com |
2024-12-09 14:00:00 |
Czytaj oryginał (ang.) |
| Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis |
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following. |
businesswire.com |
2024-12-08 13:00:00 |
Czytaj oryginał (ang.) |
| Genmab Is Too Attractive To Ignore |
Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio. |
seekingalpha.com |
2024-12-08 10:12:09 |
Czytaj oryginał (ang.) |
| Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) |
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results f. |
businesswire.com |
2024-12-07 21:00:00 |
Czytaj oryginał (ang.) |
| Scancell strikes deal worth up to $630m with Genmab |
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish biotech exclusive global rights to develop and commercialise a monoclonal antibody from the UK drug developer's GlyMab platform. |
proactiveinvestors.co.uk |
2024-12-04 05:04:54 |
Czytaj oryginał (ang.) |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise |
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. |
globenewswire.com |
2024-12-03 18:35:00 |
Czytaj oryginał (ang.) |